Business Context and Reporting Period
Company: DNA X, Inc. (Ticker: SONM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2026
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
This filing reports a specific financing transaction rather than periodic financial results (revenue, profit, or cash flow). Key transaction metrics include:
- Securities Issued: 1,346,531 shares of non-voting Series B Convertible Preferred Stock.
- Purchase Price: $6.00 per share.
- Aggregate Offering Price: $8.1 million.
- Payment Structure: $5.0 million in cash and $3.1 million via cancellation of an outstanding convertible promissory note issued in May 2026.
- Investor: DNA Holdings Venture, Inc. (a holder of >5% of outstanding stock and an entity associated with Board member Scott Walker).
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Agreements
The filing details the following material changes and agreements entered into on June 29, 2026:
- Debt Cancellation: $3.1 million of existing debt (convertible promissory note) was converted into equity as part of the transaction.
- Registration Rights: DNA Holdings received customary registration rights for the Common Stock issuable upon conversion of the Series B Preferred Stock. The Company must file a resale registration statement within 30 days of stockholder approval.
- Consulting Agreement: The Company expects to enter into an advisory agreement with DNA Holdings, Scott Walker, and Brock Pierce. In exchange for services and non-compete commitments, the consultants will receive an aggregate of 2,494,000 shares of Common Stock (subject to stockholder approval).
- Participation Rights: DNA Holdings has the right to participate in future equity and debt financings for 12 months, capped at 50% of the principal amount of securities sold in such financings.
Terms of Series B Preferred Stock and Risks
Security Terms:
- Voting: Non-voting, except for specific protective provisions (e.g., changes to rights, creation of senior securities).
- Conversion: Automatically converts to Common Stock at $6.00 per share following stockholder approval. Not convertible prior to approval.
- Liquidation: 1x Stated Value preference over Common Stock.
- Dividends: Payable only on an as-converted basis if dividends are paid on Common Stock.
- Redemption: Not redeemable by the Company or the holder.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions and stockholder approval for the issuance of underlying Common Stock.
- Registration Deadlines: The Company faces liquidated damages if it fails to meet specific deadlines for filing and maintaining the effectiveness of the resale registration statement.
- Forward-Looking Statements: The filing includes standard disclaimers regarding uncertainties in future events, including the timing of the transaction completion and use of proceeds.
Investor Verification Checklist
- Verify the status of the stockholder approval required for the conversion of Series B Preferred Stock and the issuance of consulting shares.
- Confirm the exact terms of the $3.1 million convertible promissory note cancelled in this transaction.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions on future issuances.
- Monitor the filing of the resale registration statement (Form S-3 or S-1) within the 30-day window post-approval to avoid liquidated damages.
- Assess the impact of the 2,494,000 consulting shares on future dilution once stockholder approval is obtained.